Clinical data on the antitumor activity of hydrazine sulfate

Gershanovich, M.L.; Danova, L.A.; Kondratyev, V.B.; Malyugina, L.L.; Stukov, A.N.; Seitz, J.F.; Filov, V.A.

Cancer Treatment Reports 60(7): 933-935


ISSN/ISBN: 0361-5960
PMID: 1009524
Accession: 004967327

Download citation:  

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Among specific manifestations of the subjective effect of hydrazine sulfate in the treatment of malignant diseases is the peculiar effect it has on the psychological status of patients. In the 1st weeks of drug administration in adequate doses, a considerable number of patients showed improvement in their disposition which was accompanied by a less critical evaluation of their condition. There was an overestimation of their mobile and other capabilities which bordered on euphoria. Even when no objective effects could be detected, the mood stimulating activity of the drug persisted until death. Subjective manifestations of the therapeutic effect of the drug were seen in 51 of 95 patients (53.7%). This therapeutic effect of hydrazine sulfate was accompanied by moderate toxicity, without any myelodepressive action. Doses of 180 mg daily induced dyspeptic signs (nausea and vomiting [14%]), which disappeared without any specific treatment on drug removal or dose reduction by 1/3. General toxic effects (dizziness, general excitement, insomnia) occurred in 11% of the patients and were rather mild (1 patient had visual and auditory hallucinations). Of greatest significance was a polyneuritic syndrome (2.9% of the patients) which occurred only after prolonged treatment (2-5 mo.) and completely disappeared after 1.5 mo. of therapy.